Specific Risk Factors for Development Cerebrovascular Disorders in Patients with Chronic Kidney Disease
Article Sidebar
Main Article Content
Abstract
Cerebral vascular disorders are one of the leading causes of disability and mortality in patients with chronic kidney disease (CKD). The article presents the currently available data on risk factors (RF) for the development of cerebrovascular disorders in pre-dialysis patients with CKD. Two groups of RF are identified: traditional and non-traditional (specific). Traditional RF, which include arterial hypertension, diabetes mellitus and hypercholesterolemia, independently affect the cerebral vascular bed and get worse against the background of CKD. Specific RF is associated with features of the CKD pathogenesis. It includes increased blood levels of homocysteine, β2-microglobulin, impaired calcium-phosphorus metabolism, accumulation of uremic toxins and toxins of intestinal bacteria, anemia and other factors. In the present review, special attention is paid to specific RF and pathogenetic mechanisms of the development of cerebrovascular disorders in predialysis patients with CKD.
Article Details
Section
How to Cite
References
Barsoum, R.S. Chronic kidney disease in the developing world. N. Engl. J. Med. 2006, 354, 997–999. [CrossRef] [PubMed]
Nugent, R.A.; Fathima, S.F.; Feigl, A.B.; Chyung, D. The burden of Chronic Kidney Disease on developing nations: A 21st century challenge in global health. Nephron Clin. Pract. 2011, 118, c269–c277. [CrossRef] [PubMed]
Manjunath, G.; Tighiouart, H.; Ibrahim, H.; MacLeod, B.; Salem, D.N.; Griffith, J.L.; Coresh, J.; Levey, A.S.; Sarnak, M.J. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. J. Am. Coll. Cardiol. 2003, 63, 1121–1129. [CrossRef]
Anavekar, N.S.; Pfeffer, M.A. Cardiovascular risk in chronic kidney disease. Kidney Int. 2004, 66, S11–S15. [CrossRef]
Go, A.S.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Hsu, C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004, 351, 1296–1305. [CrossRef] [PubMed] Life 2021, 11, 210 11 of 12
Sarnak, M.J.; Levey, A.S.; Schoolwerth, A.C.; Coresh, J.; Culleton, B.; Hamm, L.L.; McCullough, P.A.; Kasiske, B.L.; Michael, E.K.; Klag, J.; et al. Wilson Kidney Disease as a Risk Factor for Development of Cardiovascular Disease. Circulation 2003, 108, 2154–2169. [CrossRef]
Irie, F.; Iso, H.; Sairenchi, T.; Fukasawa, N.; Yamagishi, K.; Ikehara, S.; Kanashiki, M.; Saito, Y.; Ota, H.; Nose, T. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006, 69, 1264–1271. [CrossRef]
Kuo, C.C.; Lee, C.T.; Ho, S.C.; Kuo, H.W.; Wu, T.N.; Yang, C.Y. Haemodialysis and the risk of stroke: A population-based cohort study in taiwan, a country of high incidence of end-stage renal disease. Nephrology 2012, 17, 243–248. [CrossRef] [PubMed]
El Husseini, N.; Kaskar, O.; Goldstein, L.B. Chronic kidney disease and stroke. Adv. Chronic Kidney Dis. 2014, 21, 500–508. [CrossRef] [PubMed]
Toyoda, K.; Ninomiya, T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol. 2014, 13, 823–833. [CrossRef]
Hojs Fabjan, T.; Hojs, R. Stroke and renal dysfunction. Eur. J. Intern. Med. 2014, 25, 18–24. [CrossRef] [PubMed]
Koren-Morag, N.; Goldbourt, U.; Tanne, D. Renal dysfunction and risk of ischemic stroke or tia in patients with cardiovascular disease. Neurology 2006, 67, 224–228. [CrossRef] [PubMed]
Kumai, Y.; Kamouchi, M.; Hata, J.; Ago, T.; Kitayama, J.; Nakane, H.; Sugimori, H.; Kitazono, T. Proteinuria and clinical outcomes after ischemic stroke. Neurology 2012, 78, 1909–1915. [CrossRef] [PubMed]
Sozio, S.M.; Armstrong, P.A.; Coresh, J.; Jaar, B.G.; Fink, N.E.; Plantinga, L.C.; Powe, N.R.; Parekh, R.S. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: The choices for healthy outcomes in caring for esrd (choice) study. Am. J. Kidney Dis. 2009, 54, 468–477. [CrossRef] [PubMed]
Hojs Fabjan, T.; Hojs, R.; Tetickovic, E.; Pecovnik Balon, B. Ischaemic stroke–impact of renal dysfunction on in-hospital mortality. Eur. J. Neurol. 2007, 14, 1351–1356. [CrossRef] [PubMed]
Tsagalis, G.; Akrivos, T.; Alevizaki, M.; Manios, E.; Stamatellopoulos, K.; Laggouranis, A.; Vemmos, K.N. Renal dysfunction in acute stroke: An independent predictor of long-term all combined vascular events and overall mortality. Nephrol. Dial. Transplant. 2009, 24, 194–200. [CrossRef] [PubMed]
Allen, C.L.; Bayraktutan, U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int. J. Stroke 2009, 4, 461–470. [CrossRef] [PubMed]
Yu, G.; Liang, Y.; Zheng, S.; Zhang, H. Inhibition of myeloperoxidase by n-acetyl lysyltyrosylcysteine amide reduces oxidative stress-mediated inflammation, neuronal damage, and neural stem cell injury in a murine model of stroke. J. Pharmacol. Exp. Ther. 2018, 364, 311–322. [CrossRef] [PubMed]
Watanabe A. Cerebral microbleeds and intracerebral hemorrhages in patients on maintenance hemodialysis. J Stroke Cerebrovasc Dis 2007; 16: 30–33
Yokoyama S, Hirano H, Uomizu K et al. High incidence of microbleeds in hemodialysis patients detected by T2*-weighted gradient-echo magnetic resonance imaging. Neurol Med Chir (Tokyo) 2005; 45: 556–560
Naganuma T, Takemoto Y, Yamasaki T et al. Factors associated with silent cerebral microbleeds in hemodialysis patients. Clin Nephrol 2011; 75: 346–355
Murray AM, Seliger S, Lakshminarayan K et al. Incidence of stroke before and after dialysis initiation in older patients. J Am Soc Nephrol 2013; 24: 1166–1173 23. Madero M, Sarnak MJ. Does hemodialysis hurt the brain? Semin Dial 2011; 24: 266–268
Toyoda K, Fujii K, Ando T et al. Incidence, etiology, and outcome of stroke in patients on continuous ambulatory peritoneal dialysis. Cerebrovasc Dis 2004; 17: 98–105
Hojs Fabjan T, Hojs R. Stroke and renal dysfunction. Eur J Intern Med 2014; 25: 18–24
Koren-Morag N, Goldbourt U, Tanne D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology 2006; 67: 224–228
Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010, 25, 603–605. [CrossRef] [PubMed]
DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. Controlled Clin. Trials 1986, 7, 177–188. [CrossRef] [PubMed] Medicines 2023, 10, 46 14 of 14 29. Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560. [CrossRef] [PubMed]
Easterbrook, P.J.; Gopalan, R.; Berlin, J.; Matthews, D.R. Publication bias in clinical research. Lancet 1991, 337, 867–872. [CrossRef]
FONG, V.; Kamaruzaman, L.; Daud, W.W.; Mohd, R.; Tan, H.; Erica, Y.; Mustafar, R. POS-617 contrast-induced encephalopathy in a patient with end-stage renal disease. Kidney Int. Rep. 2022, 7, S264. [CrossRef]
Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634. [CrossRef]
Murumkar, V.; Peer, S.; Jabeen, S.; Chauhan, R.S.; Saini, J.; Aravinda, R.H.; Lanka, V.; Kulkarni, G.B. Contrast-Induced Encephalopathy—An Unusual Complication Following Endovascular Interventions in the Anterior Circulation. Ann. Indian Acad. Neurol. 2021, 24, 635–639. [CrossRef] [PubMed]
Hamra, M.; Bakhit, Y.; Khan, M.; Moore, R. Case report and literature review on contrast-induced encephalopathy. Future Cardiol. 2017, 13, 331–335. [CrossRef] [PubMed]
Pokersnik, J.A.; Liu, L.; Simon, E.L. Contrast-induced encephalopathy presenting as acute subarachnoid hemorrhage. Am. J. Emerg. Med. 2018, 36, 1122.e3–1122.e4. [CrossRef] [PubMed]
Mescolotte, G.M.; Silva, F.R.D.; Afonso, S.; Pamplona, J.; Moreno, R. Reversible contrast-induced encephalopathy after coil embolization of epistaxis. Rev. Bras. Ter. Intensiva 2021, 33, 331–335. [CrossRef] [PubMed]
Senthilkumaran, S.; Balamurugan, N.; Jena, N.N.; Thirumalaikolundusubramanian, P. Contrast-induced encephalopathy and diagnostic modalities—Can it make a difference? Am. J. Emerg. Med. 2018, 36, 2328. [CrossRef]
Ramalho, J.; Semelka, R.C.; Ramalho, M.; Nunes, R.H.; AlObaidy, M.; Castillo, M. Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update. AJNR Am. J. Neuroradiol. 2016, 37, 1192–1198. [CrossRef]